“Phal-501 can be a great drug that has the potential to change the lives of many patients with severe COPD.”
Welcome to PharmaLundensis!
PharmaLundensis develops drugs that bind and excrete heavy metals such as mercury, lead and cadmium from the body. This is expected to bring significant health improvements in a number of diseases.
Function and benefits of Phal-501
Phal-501 provides a strong and long-lasting binding of mercury and probably also lead and cadmium. Furthermore, Phal-501 is expected to have very small side effects, if any, as the substance never enters the bloodstream. After swallowing, Phal-501 binds heavy metals in the intestine and then goes directly into the stool. This allows the body’s heavy metals to be “leached out” and rendered harmless.
News
Positive results in animal toxicology tests with Phal-501
The pilot animal toxicology study with Phal-501 in mice has now been completed. The study...
Publication of patent application for Phal-501
The European Patent Office (EPO) has now published PharmaLundensis’ patent application that protects Phal-501 and...
Now performing toxicological tests on mice with Phal-501
PharmaLundensis is now performing pilot in-vivo toxicological tests on mice with Phal-501. The study examines ...